Trinity Biotech plc (TRIB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Trinity Biotech plc (TRIB) has a cash flow conversion efficiency ratio of 0.001x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-71.45K) by net assets ($-54.72 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See net asset quality index of Trinity Biotech plc to measure how much of total assets are equity-financed.
Trinity Biotech plc - Cash Flow Conversion Efficiency Trend (1993–2024)
This chart illustrates how Trinity Biotech plc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Trinity Biotech plc (TRIB) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Trinity Biotech plc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Trinity Biotech plc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
DT&C Co. Ltd
KQ:187220
|
0.005x |
|
Bharat Road Network Limited
NSE:BRNL
|
-0.109x |
|
Pelikan International Corp
KLSE:5231
|
-0.039x |
|
Rackla Metals Inc
V:RAK
|
-0.294x |
|
CPR Gomu Industrial PCL
BK:CPR
|
0.020x |
|
Genolution Inc.
KQ:225220
|
-0.013x |
|
NEXTCHIP Co. Ltd
KQ:092600
|
-0.132x |
|
Australian Vintage Ltd
AU:AVG
|
-0.125x |
Annual Cash Flow Conversion Efficiency for Trinity Biotech plc (1993–2024)
The table below shows the annual cash flow conversion efficiency of Trinity Biotech plc from 1993 to 2024. For the full company profile with market capitalisation and key ratios, see TRIB company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-35.18 Million | $-4.19 Million | 0.119x | -75.31% |
| 2023-12-31 | $-23.95 Million | $-11.56 Million | 0.483x | +14.01% |
| 2022-12-31 | $-2.18 Million | $-921.00K | 0.423x | +101.02% |
| 2021-12-31 | $-319.00K | $13.24 Million | -41.498x | -287.64% |
| 2020-12-31 | $-2.22 Million | $23.75 Million | -10.705x | -1021.70% |
| 2019-12-31 | $4.71 Million | $5.47 Million | 1.161x | +637.81% |
| 2018-12-31 | $44.05 Million | $6.93 Million | 0.157x | -15.26% |
| 2017-12-31 | $65.20 Million | $12.11 Million | 0.186x | +46.68% |
| 2016-12-31 | $108.73 Million | $13.77 Million | 0.127x | +119.62% |
| 2015-12-31 | $213.89 Million | $12.34 Million | 0.058x | -27.88% |
| 2014-12-31 | $196.97 Million | $15.75 Million | 0.080x | +25.02% |
| 2013-12-31 | $183.01 Million | $11.71 Million | 0.064x | -45.98% |
| 2012-12-31 | $169.38 Million | $20.06 Million | 0.118x | -12.52% |
| 2011-12-31 | $151.33 Million | $20.48 Million | 0.135x | -17.11% |
| 2010-12-31 | $141.29 Million | $23.07 Million | 0.163x | -12.05% |
| 2009-12-31 | $79.34 Million | $14.73 Million | 0.186x | +14.05% |
| 2008-12-31 | $65.91 Million | $10.73 Million | 0.163x | +45.14% |
| 2007-12-31 | $136.84 Million | $15.35 Million | 0.112x | +154.62% |
| 2006-12-31 | $167.26 Million | $7.37 Million | 0.044x | -36.08% |
| 2005-12-31 | $133.62 Million | $9.21 Million | 0.069x | +18957.79% |
| 2004-12-31 | $116.14 Million | $42.00K | 0.000x | -99.19% |
| 2003-12-31 | $80.26 Million | $3.60 Million | 0.045x | -75.75% |
| 2002-12-31 | $62.91 Million | $11.65 Million | 0.185x | +106.90% |
| 2001-12-31 | $56.53 Million | $5.06 Million | 0.090x | +63.09% |
| 2000-12-31 | $55.04 Million | $3.02 Million | 0.055x | -67.36% |
| 1999-12-31 | $22.72 Million | $3.82 Million | 0.168x | +345.55% |
| 1998-12-31 | $14.60 Million | $-1.00 Million | -0.068x | +65.26% |
| 1997-12-31 | $7.10 Million | $-1.40 Million | -0.197x | +41.94% |
| 1996-12-31 | $10.60 Million | $-3.60 Million | -0.340x | -218.40% |
| 1995-12-31 | $7.50 Million | $-800.00K | -0.107x | +95.53% |
| 1994-12-31 | $1.30 Million | $-3.10 Million | -2.385x | -208.01% |
| 1993-12-31 | $3.10 Million | $-2.40 Million | -0.774x | -- |
About Trinity Biotech plc
Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Asia, Africa, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; se… Read more